Brief: XORTX Therapeutics Inc Announces Launch Of XRX-026 Drug Development Program To Treat Gout
06/01/2025 23:03
Jan 6 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX THERAPEUTICS INC: ANNOUNCES LAUNCH OF XRX-026 DRUG
DEVELOPMENT PROGRAM TO TREAT GOUT
* XORTX THERAPEUTICS INC: PROGRAM TO FOCUS ON TREATMENT OF
INDIVIDUALS WHO HAVE GOUT AND ARE INTOLERANT TO ALLOPURINOL
Source text: ID:n0001171843-25-000052
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering